CBD / CBN

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: cbd-cbn · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

No clinical interaction data. CBD inhibits UGT1A9 and CYP enzymes in vitro, so psilocin levels could rise slightly in theory. Full-spectrum products contain trace THC.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

UGT inhibition (theoretical effect on psilocin levels): Inhibits UGT enzymes (glucuronidation), the main route by which the body clears psilocin. In theory this could raise psilocin levels or lengthen the effect. Sources [1]

03 State rules

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Brunton LL, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed. McGraw Hill, 2023., p. 411 — Table 20–3: cannabidiol inhibits UGT1A9
US FDA consumer or public-health page (per-entry link)
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Report an error in this record →